Prime Medicine (PRME) Capital Expenditures (2021 - 2025)
Prime Medicine (PRME) posted Capital Expenditures of $290000.0 for Q4 2025, down 92.91% on a QoQ basis from $4.1 million in Q3 2025, and down 72.2% year-over-year from $1.0 million in Q4 2024.
Prime Medicine (PRME) Capital Expenditures (2021 - 2025) Analysis & Trends
Prime Medicine's Capital Expenditures history runs 5 years deep, the most recent figure standing at $290000.0 for Q4 2025.
- Quarterly Capital Expenditures fell 72.2% year-over-year to $290000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $2.1 million (down 23.11% YoY) and the FY2025 annual result came in at $4.5 million, up 292.63% from the prior year.
- Capital Expenditures was $290000.0 for Q4 2025 at Prime Medicine, down from $4.1 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $8.2 million in Q4 2023 and bottomed at -$10.3 million in Q4 2022.
- A 5-year average of $948941.2 and a median of $1.0 million in 2024 frame the typical range for Capital Expenditures.
- Peak annual rise in Capital Expenditures reached 363.64% in 2024, while the deepest fall reached 1967.84% in 2024.
- Prime Medicine's Capital Expenditures stood at $754000.0 in 2021, then slumped by 1467.64% to -$10.3 million in 2022, then surged by 179.63% to $8.2 million in 2023, then slumped by 87.3% to $1.0 million in 2024, then plunged by 72.2% to $290000.0 in 2025.
- Business Quant data shows PRME's Capital Expenditures at $290000.0 in Q4 2025, $4.1 million in Q3 2025, and -$2.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Prime Medicine | 525.98 Mn | 525.98 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 290,000.00 |
| Dec 31, 2025 | 290,000.00 |
| Sep 30, 2025 | 4.09 Mn |
| Sep 30, 2025 | 4.09 Mn |
| Jun 30, 2025 | -2.27 Mn |
| Jun 30, 2025 | -2.27 Mn |
| Mar 31, 2025 | 2.42 Mn |
| Mar 31, 2025 | 2.42 Mn |
| Dec 31, 2024 | 1.04 Mn |
| Dec 31, 2024 | 1.04 Mn |
| Sep 30, 2024 | -4.12 Mn |
| Sep 30, 2024 | -4.12 Mn |
| Jun 30, 2024 | 3.39 Mn |
| Jun 30, 2024 | 3.39 Mn |
| Mar 31, 2024 | 833,000.00 |
| Mar 31, 2024 | 833,000.00 |
| Dec 31, 2023 | 8.21 Mn |
| Dec 31, 2023 | 8.21 Mn |
| Sep 30, 2023 | -199,000.00 |
| Sep 30, 2023 | -199,000.00 |